AERI Aerie Pharmaceuticals, Inc.

40.80
-0.25  -1%
Previous Close 41.05
Open 41.10
Price To book 16.41
Market Cap 1.37B
Shares 33,634,000
Volume 207,624
Short Ratio 7.09
Av. Daily Volume 401,016

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 3 Mercury 1 data released September 14, 2016. Primary endpoint met. Mercury 2 trial data due 2Q 2017.
Roclatan - Mercury trials
Glaucoma
PDUFA date February 28, 2018. Advisory Committee planned.
Rhopressa
Glaucoma

Latest News

  1. GlycoMimetics (GLYC) Shows Strength: Stock Jumps 98.7%
  2. ImmunoGen (IMGN) Shows Strength: Stock Up 14.2% Higher
  3. Cardiome Pharma (CRME) Looks Good: Stock Moves 6.1% Higher
  4. Aerie's (AERI) Rhopressa NDA Sufficient for FDA Review
  5. Aerie Pharmaceuticals Announces New Hires
  6. Are Options Traders Betting on a Big Move in Aerie Pharmaceuticals (AERI) Stock?
  7. Aerie Pharmaceuticals Announces FDA Acceptance of NDA Submission for Rhopressa™ (netarsudil ophthalmic solution) 0.02%
  8. Blog Coverage: Merck Receives European Commission Approval for the Treatment of Hodgkin Lymphoma
  9. Aerie (AERI) Posts Wider-Than-Expected Q1 Loss, Expenses Up
  10. Aerie reports 1Q loss
  11. Aerie Pharmaceuticals Reports First Quarter 2017 Financial Results and Provides Business Update
  12. Investor Network: Aerie Pharmaceuticals, Inc. to Host Earnings Call
  13. What Awaits Aerie Pharmaceuticals (AERI) in Q1 Earnings?
  14. Aerie Pharmaceuticals to Announce First Quarter 2017 Financial Results and Host Conference Call on Tuesday, May 2, 2017
  15. Aerie Pharmaceuticals Announces Appointment of Raymond S. Wysmierski as Director of Compliance
  16. Implied Volatility Surging for Aerie Pharmaceuticals (AERI) Stock Options
  17. Aerie Reports Positive Data on Ophthalmic Drug Rhopressa
  18. After-hours buzz: PIR, HBI & AERI
  19. Aerie Pharmaceuticals Reports Positive Rocket 4 Six-Month Topline Safety and Efficacy Results for RhopressaTM (netarsudil ophthalmic solution) 0.02%
  20. 3 Clinical-Stage Biotech Stocks That Could Be About to Strike It Rich